Roche to present obesity‑portfolio data at ADA 2026
- Enicepatide (CT-388), a cAMP signal‑biased dual GLP-1/GIP agonist, and petrelintide, a long-acting amylin analog, showed Phase II efficacy with favorable tolerability.
- Roche is advancing both assets toward Phase III and will initiate a Phase II multi-arm fixed-dose combination trial mid-2026.
- Principal studies: CT388-103 (48-week enicepatide Phase II), CT388-104 (enicepatide in people with obesity and T2D), ZUPREME-1 (petrelintide Phase II) and ongoing ZUPREME-2 (petrelintide vs placebo in obesity/T2D).
- ADA 2026 presentations include late-breaking posters and an e-theater reporting clinical weight-loss outcomes and preclinical data on eating pattern and gastric emptying.
Key findings
Late‑breaking Phase II data presented at ADA show enicepatide and petrelintide produce clinically meaningful weight loss with favorable safety and tolerability, supporting potential for broader, sustained use in people with overweight or obesity.
Assets and mechanisms
Enicepatide (CT‑388) is a once‑weekly, cAMP signal‑biased dual GLP‑1/GIP receptor agonist designed to minimise beta‑arrestin recruitment and receptor desensitisation, aiming for prolonged pharmacological activity; petrelintide is a long‑acting, once‑weekly human amylin analog engineered for chemical stability and co‑formulation potential that promotes satiety and may restore leptin sensitivity.
Clinical program and timelines
Key studies include CT388‑103 (48‑week Phase II enicepatide), CT388‑104 (enicepatide in people with obesity and T2D), ZUPREME‑1 (petrelintide Phase II) and ongoing ZUPREME‑2 (petrelintide vs placebo in obesity/T2D); both assets are being advanced toward Phase III and a Phase II multi‑arm fixed‑dose combination trial is planned to start mid‑2026.
ADA presentations and supporting data
Roche will report late‑breaking clinical posters and an e‑theater for enicepatide (late‑breaking poster 7 June; e‑theater 8 June) and multiple petrelintide presentations including a scientific symposium (5 June), late‑breaking poster (7 June; ePoster 6 June) plus preclinical posters showing distinct effects on eating patterns, maintained locomotor activity versus semaglutide, and no delay in gastric emptying.
Source: Roche
